1. Home
  2. NCTY vs LUNG Comparison

NCTY vs LUNG Comparison

Compare NCTY & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The9 Limited American Depository Shares

NCTY

The9 Limited American Depository Shares

HOLD

Current Price

$4.93

Market Cap

61.7M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.98

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCTY
LUNG
Founded
1999
1995
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.7M
57.9M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
NCTY
LUNG
Price
$4.93
$1.98
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
168.9K
629.0K
Earning Date
03-27-2015
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$3.14
$1.13
52 Week High
$11.60
$2.89

Technical Indicators

Market Signals
Indicator
NCTY
LUNG
Relative Strength Index (RSI) 55.11 69.39
Support Level $4.20 $1.27
Resistance Level $5.65 $2.14
Average True Range (ATR) 0.51 0.17
MACD 0.11 0.09
Stochastic Oscillator 87.85 83.08

Price Performance

Historical Comparison
NCTY
LUNG

About NCTY The9 Limited American Depository Shares

The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: